Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel
SAN DIEGO, CA, June 22, 2026 — Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss ...
Nanoscope Therapeutics Announces the Publication of MCO-010 Gene Therapy Demonstrating Vision-Restoring and Disease-Modifying Effects in Stargardt Disease Preclinical Study
Single intravitreal injection of MCO-010 produced sustained improvement in visually guided behavior in preclinical model of Stargardt diseaseMCO-010-treatment showed significant increases in retinal p ...
Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
DALLAS, May 27, 2026 -- Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision ...
Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting
Presentations will highlight the ongoing research behind potential bilateral and color vision benefits of Nanoscope's optogenetic therapy platformDALLAS, May 11, 2026 -- Nanoscope Therapeutics Inc., a ...
Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2026 Annual Meetings
Presentations to highlight Nanoscope’s best-in-class efficacy, durability, and safety of optogenetic therapy platforms DALLAS, TX, April 20th, 2026 – Nanoscope Therapeutics Inc., a biotechnology compa ...
Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness
Veteran ophthalmology executive with over 30 years of experience spanning R&D, manufacturing, quality, commercial strategy, and franchise leadershipFormer Vice President and Global Head of Retina ...
Nanoscope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO-010, Expands Global Regulatory Leadership in Vision Restoration
DALLAS, March 30, 2026 -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and v ...
Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease
DALLAS, March 23, 2026 -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photorece ...
Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting
Dr. Christine N. Kay to Present Multivariant Analysis of 3-Year RESTORE and REMAIN Data, Identifying Patient and Disease Characteristics Associated with Best Outcomes in Retinitis Pigmentosa Patients ...
Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases – A First for a Retinal Gene Therapy
Japan's Ministry of Health, Labor and Welfare (MHLW) grants MCO-010 Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations, enabling an accelerated regulatory pathway to treat ...
Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration
DALLAS, Jan. 7, 2026 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vis ...
Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Company to highlight regulatory progress, clinical trial momentum, and multiple value-driving milestones expected in 2026DALLAS, Jan. 5, 2026 -- Nanoscope Therapeutics Inc., a biotechnology company co ...
Nanoscope Therapeutics’ MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress
DALLAS, Dec. 2, 2025 -- NanoscopeTherapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and visi ...
Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025
DALLAS, Nov. 17, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vis ...
Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a five-year follow-up of participants who received a single intravitreal i ...
Nanoscope Therapeutics President and Chief Scientific Officer Dr. Samarendra Mohanty to Be Featured Speaker at 2025 ISPE Annual Meeting and Expo
DALLAS, Oct. 27, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vi ...
Nanoscope Therapeutics Announces Durable 3-Year Vision Improvements from REMAIN Study of MCO-010 in Retinitis Pigmentosa
REMAIN results showed sustained, 3-line vision gains vs baseline through 152 weeks for MCO-010 in patients having severe vision loss from retinitis pigmentosa, and a favorable safety profileThe data f ...
Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting
DALLAS, Oct. 13, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vis ...
Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations
European Medicines Agency grants MCO-010 five Orphan designations across a wide spectrum of retinal diseases involving photoreceptor loss, including syndromic and non-syndromic, rod- and cone-dominant ...
Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting
Talks highlight efficacy, durability, and safety of Nanoscope's MCO (multi-characteristic opsin) optogenetic therapy platform Data forms the foundation for recent rolling Biologics License Application ...